Reshaping ApoE4 and Alzheimer's Brains with ApoE2
用 ApoE2 重塑 ApoE4 和阿尔茨海默病大脑
基本信息
- 批准号:10549826
- 负责人:
- 金额:$ 58.55万
- 依托单位:
- 依托单位国家:美国
- 项目类别:
- 财政年份:2022
- 资助国家:美国
- 起止时间:2022-01-15 至 2026-11-30
- 项目状态:未结题
- 来源:
- 关键词:AddressAdverse reactionsAffectAgeAllelesAlzheimer&aposs DiseaseAlzheimer&aposs disease brainAmericanAmyloidApolipoprotein EBiologicalBlood - brain barrier anatomyBrainCadherinsCodeDataDepositionDevelopmentDiseaseDrug TargetingE-CadherinEarly Onset Familial Alzheimer&aposs DiseaseGenesGenotypeGlucoseGlycoproteinsGoalsHealthHippocampusHomeostasisHumanInterventionKnock-in MouseMediatingMetabolicMetabolismMethodsModelingMolecularMusNatureNeuronsOutcomeOutcomes ResearchPathogenesisPathologyPeptidesPersonsPhysiologicalPlayPredispositionPreparationPreventionProductionProtein IsoformsProteinsRecombinantsRegimenResearchResearch Project SummariesRiskRoleShapesSignal TransductionSynapsesTherapeuticTranslatingTranslationsUp-Regulationaging brainapolipoprotein E-2apolipoprotein E-3apolipoprotein E-4cognitive functiondesignfamilial Alzheimer diseasefightingglucose metabolismhigh riskhumanized mouseimprovedinnovationinsightlipidomicsmouse modelmutantneuroprotectionnovelpreventproteostasisresiliencesexsuccesstau Proteinstrend
项目摘要
PROJECT SUMMARY
The research we propose in this application seeks to translate our recent understanding of the
neuroprotective mechanism associated with the human apolipoprotein E2 (ApoE2) genotype into a
therapeutic opportunity to prevent and treat Alzheimer's disease (AD). The overarching hypotheses
are that introduction of human ApoE2 protein into high-risk ApoE4 and AD brains positively alters the
course of brain aging or disease pathogenesis by bolstering brain resilience through enhanced
glycolytic metabolism, which subsequently improves glucose utilization, protein homeostasis, and
synaptic activity. In preparation, we have achieved three major milestones critical to the success
of this translational endeavor: (1) development of a method for the production of physiologically
relevant and human-compatible recombinant ApoE2 (rhApoE2) glycoprotein that possesses biological
functionality comparable to endogenous human ApoE2; (2) development of a noninvasive approach
for brain delivery of rhApoE2 glycoprotein via modulation of cadherin interactions on the blood-brain
barrier (BBB), which induces neuroprotective signaling in ApoE4 brains; and (3) development of novel
humanized knock-in mouse models that respectively target human sporadic (sAD) and familial AD
(fAD), which are expected to provide high predictive validity for translating bench successes to
bedside. The proposed studies will pursue three specific aims. Building on our initial success, the
objective of the first aim is to determine the therapeutically optimal regimen for delivery of rhApoE2
glycoprotein that will result in deposition of rhApoE2 throughout cortical and hippocampal regions and
upregulation of brain glycolytic metabolism without eliciting adverse reactions. The objective of the
second aim is to evaluate the therapeutic impact of rhApoE2 delivery, in combination with age and
sex, on brain changes associated with sAD in humanized mouse models that express physiological
levels of human ApoE3 or ApoE4 and human wild-type APP proteins. The third aim will be
investigated in humanized mouse models that express physiological levels of human ApoE3 or ApoE4
and human mutant APP proteins to evaluate the therapeutic impact of rhApoE2 delivery on brain
changes associated with fAD, and how the rhApoE2-mediated effects are modified by a combination
of age, sex, ApoE genotype, and disease status. Our overall goals for the proposed research are
to establish the plausibility of targeting brain metabolic resilience as a disease-modifying strategy and
generate proof of concept as to whether a rhApoE2-based protein therapy can potentially be
developed into an effective and safe intervention for AD.
项目摘要
我们在本申请中提出的研究旨在将我们最近对
与人载脂蛋白E2(ApoE 2)基因型相关的神经保护机制,
预防和治疗阿尔茨海默病(AD)的治疗机会。总体假设
将人ApoE 2蛋白引入高风险ApoE 4和AD脑中,
脑老化或疾病的发病机制,通过增强大脑的弹性,
糖酵解代谢,其随后改善葡萄糖利用、蛋白质稳态,
突触活动。在筹备过程中,我们实现了三个对成功至关重要的重要里程碑。
(1)开发一种生产生理学上的
具有生物学活性的相关的和人相容的重组ApoE 2(rhApoE 2)糖蛋白
功能与内源性人ApoE 2相当;(2)开发非侵入性方法
用于通过调节钙粘蛋白在血脑上的相互作用向脑递送rhApoE 2糖蛋白
屏障(BBB),其在ApoE 4脑中诱导神经保护性信号传导;和(3)开发新的
分别靶向人散发性(sAD)和家族性AD的人源化敲入小鼠模型
(fAD),预计将为将实验室成功转化为
床边拟议的研究将追求三个具体目标。在初步成功的基础上,
第一个目的是确定用于递送rhApoE 2的治疗最佳方案
糖蛋白,其将导致rhApoE 2在整个皮质和海马区域沉积,
上调脑糖酵解代谢而不引起不良反应。的目的
第二个目的是评估rhApoE 2递送的治疗效果,与年龄和
在表达生理学信号的人源化小鼠模型中,
人ApoE 3或ApoE 4和人野生型APP蛋白的水平。第三个目标是
在表达生理水平的人ApoE 3或ApoE 4的人源化小鼠模型中研究
和人突变APP蛋白,以评估rhApoE 2递送对脑的治疗影响
与fAD相关的变化,以及rhApoE 2介导的效应如何通过联合用药进行修饰
年龄、性别、ApoE基因型和疾病状态。我们对拟议研究的总体目标是
建立靶向脑代谢恢复作为疾病改善策略的可行性,
生成关于基于rhApoE 2的蛋白质疗法是否可能
发展成为一种有效和安全的AD干预措施。
项目成果
期刊论文数量(0)
专著数量(0)
科研奖励数量(0)
会议论文数量(0)
专利数量(0)
数据更新时间:{{ journalArticles.updateTime }}
{{
item.title }}
{{ item.translation_title }}
- DOI:
{{ item.doi }} - 发表时间:
{{ item.publish_year }} - 期刊:
- 影响因子:{{ item.factor }}
- 作者:
{{ item.authors }} - 通讯作者:
{{ item.author }}
数据更新时间:{{ journalArticles.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ monograph.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ sciAawards.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ conferencePapers.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ patent.updateTime }}
TERUNA J. SIAHAAN其他文献
TERUNA J. SIAHAAN的其他文献
{{
item.title }}
{{ item.translation_title }}
- DOI:
{{ item.doi }} - 发表时间:
{{ item.publish_year }} - 期刊:
- 影响因子:{{ item.factor }}
- 作者:
{{ item.authors }} - 通讯作者:
{{ item.author }}
{{ truncateString('TERUNA J. SIAHAAN', 18)}}的其他基金
Reshaping ApoE4 and Alzheimer's Brains with ApoE2
用 ApoE2 重塑 ApoE4 和阿尔茨海默病大脑
- 批准号:
10363417 - 财政年份:2022
- 资助金额:
$ 58.55万 - 项目类别:
Reshaping ApoE4 and Alzheimer's Brains with ApoE2
用 ApoE2 重塑 ApoE4 和阿尔茨海默病大脑
- 批准号:
10812094 - 财政年份:2022
- 资助金额:
$ 58.55万 - 项目类别:
Modulating the BBB to Improve Drug Delivery to the Brain
调节血脑屏障以改善药物向大脑的输送
- 批准号:
8320154 - 财政年份:2011
- 资助金额:
$ 58.55万 - 项目类别:
Modulating the BBB to Improve Drug Delivery to the Brain
调节血脑屏障以改善药物向大脑的输送
- 批准号:
8492187 - 财政年份:2011
- 资助金额:
$ 58.55万 - 项目类别:
Modulating the BBB to Improve Drug Delivery to the Brain
调节血脑屏障以改善药物向大脑的输送
- 批准号:
8162174 - 财政年份:2011
- 资助金额:
$ 58.55万 - 项目类别:
Modulating the BBB to Improve Drug Delivery to the Brain
调节血脑屏障以改善药物向大脑的输送
- 批准号:
8666676 - 财政年份:2011
- 资助金额:
$ 58.55万 - 项目类别:
Targeting and Internalization Mechanism of LFA-1
LFA-1的靶向和内化机制
- 批准号:
6968983 - 财政年份:2005
- 资助金额:
$ 58.55万 - 项目类别:
Targeting and Internalization Mechanism of LFA-1
LFA-1的靶向和内化机制
- 批准号:
7209818 - 财政年份:2005
- 资助金额:
$ 58.55万 - 项目类别:
Targeting and Internalization Mechanism of LFA-1
LFA-1的靶向和内化机制
- 批准号:
7082012 - 财政年份:2005
- 资助金额:
$ 58.55万 - 项目类别:
Targeting and Internalization Mechanism of LFA-1
LFA-1的靶向和内化机制
- 批准号:
7387425 - 财政年份:2005
- 资助金额:
$ 58.55万 - 项目类别:
相似海外基金
A personalised approach to manage adverse reactions to CFTR modulator therapy in patients with cystic fibrosis
治疗囊性纤维化患者 CFTR 调节剂治疗不良反应的个性化方法
- 批准号:
MR/X00094X/1 - 财政年份:2022
- 资助金额:
$ 58.55万 - 项目类别:
Research Grant
Mechanistic study of sulfa drug-induced severe cutaneous adverse reactions by focusing on HLA-A*11:01
以HLA-A*为重点的磺胺类药物致严重皮肤不良反应机制研究11:01
- 批准号:
22K06738 - 财政年份:2022
- 资助金额:
$ 58.55万 - 项目类别:
Grant-in-Aid for Scientific Research (C)
Identifying genetic polymorphisms and elucidating polygenic architecture associated with adverse reactions due to rituximab
识别遗传多态性并阐明与利妥昔单抗不良反应相关的多基因结构
- 批准号:
22K15910 - 财政年份:2022
- 资助金额:
$ 58.55万 - 项目类别:
Grant-in-Aid for Early-Career Scientists
Severe Cutaneous Adverse Reactions Following Outpatient Antibiotic Therapy: A Population-based Study
门诊抗生素治疗后的严重皮肤不良反应:一项基于人群的研究
- 批准号:
449379 - 财政年份:2020
- 资助金额:
$ 58.55万 - 项目类别:
Studentship Programs
Significance of gamma-chain in severe cutaneous adverse reactions
伽马链在严重皮肤不良反应中的意义
- 批准号:
19K17779 - 财政年份:2019
- 资助金额:
$ 58.55万 - 项目类别:
Grant-in-Aid for Early-Career Scientists
Historical sociology of adverse reactions related to vaccination in Japan
日本疫苗接种不良反应的历史社会学
- 批准号:
18K00267 - 财政年份:2018
- 资助金额:
$ 58.55万 - 项目类别:
Grant-in-Aid for Scientific Research (C)
SEARCH (active Surveillance and Evaluation of Adverse Reactions in Canadian Healthcare) & PREVENT (Pharmacogenomics of Adverse Reaction EVEnts National Team)
SEARCH(加拿大医疗保健不良反应的主动监测和评估)
- 批准号:
379425 - 财政年份:2018
- 资助金额:
$ 58.55万 - 项目类别:
Operating Grants
IGF::OT::IGF SBIR Phase II: Topic 338 - Predictive Biomarkers of Adverse Reactions to Prostrate Cancer Radiotherapy
IGF::OT::IGF SBIR II 期:主题 338 - 前列腺癌放射治疗不良反应的预测生物标志物
- 批准号:
9576448 - 财政年份:2017
- 资助金额:
$ 58.55万 - 项目类别:
Development of in silico prediction method for idiosyncratic adverse reactions associated with HLA genotypes
与 HLA 基因型相关的特殊不良反应的计算机预测方法的开发
- 批准号:
16K15156 - 财政年份:2016
- 资助金额:
$ 58.55万 - 项目类别:
Grant-in-Aid for Challenging Exploratory Research
Characterising the Immune Response to Drugs That Cause Idiosyncratic Adverse Reactions
表征对引起特殊不良反应的药物的免疫反应
- 批准号:
367156 - 财政年份:2016
- 资助金额:
$ 58.55万 - 项目类别:
Studentship Programs